In this context, compounds with clinical uses as well as certain compounds which are in the developmental stage are included.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Objective: The use of topoisomerase II enzyme inhibitors, which have increased in importance in recent years, has been evaluated in terms of pharmaceutical chemistry and clinical use.
📊
Key Findings & Data:Objective: The use of topoisomerase II enzyme inhibitors, which have increased in importance in recent years, has been evaluated in terms of pharmaceutical chemistry and clinical use.
💡
Conclusion & Impact:In this context, compounds with clinical uses as well as certain compounds which are in the developmental stage are included.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:anticancer · clinical pharmacy · topoisomerase II
Abstract
Objective: The use of topoisomerase II enzyme inhibitors, which have increased in importance in recent years, has been evaluated in terms of pharmaceutical chemistry and clinical use. In this context, compounds with clinical uses as well as certain compounds which are in the developmental stage are included.
Özet
Amaç: Son yıllarda önemi daha da artan topoizomeraz II enzim inhibitörleri’nin Farmasötik Kimya bilimi açısından ve klinik kullanımları değerlendirilmiştir. Bu bağlamda, klinik kullanımları olan bileşiklerin yanında geliştirilme aşamasında olan bazı bileşiklere de yer verilmiştir.
FIRAT, O., YILDIZ, İ. (2020). TOPOISOMERASE II ENZYME INHIBITORS. Ankara Üniversitesi Eczacılık Fakültesi Dergisi, Cilt: 44 - Sayı: 2, 356–372. https://ajindex.com/articles/88671
Harrington, K. J. (2011). Biology of cancer. Medicine, 39(12), 689-692.
Wong, S. H., Kwong, T. N., Wu, C. Y., Yu, J. (2019). Clinical applications of gut microbiota in cancer biology. Seminars in cancer biology, 55, 28-36.
Prospective Studies Collaboration. (2002). Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. The Lancet, 360(9349), 1903-1913.
Bilge, D. B., Kantarcı, G. Mutation, Dna Damage, Repair Mechanisms And The Relation Of Cancer. Ankara Üniversitesi Eczacılık Fakültesi Dergisi, 35(2), 149-170.
Friedberg, E. C. (2003). DNA damage and repair. Nature, 421(6921), 436-440.
Doğan, İ., Yar, A. S., Ergin, V., Menevşe, S., Menevşe, A., Ekmekçi, A. (2013). L929 Fibroblast Hücre Hattında Topoizomeraz İnhibisyonunun DNA Onarımı ve Apoptozis Üzerine Etkisi. Turkish Journal of Biochemistry/Türk Biyokimya Dergisi, 38(2), 229-237. doi:10.5505/tjb.2013.32032 7. Pommier, Y. (2012). DNA topoisomerases and cancer, Springer, Berlin
Cuya, S. M., Bjornsti, M. A., van Waardenburg, R. C. (2017). DNA topoisomerase-targeting chemotherapeutics: what’s new?. Cancer chemotherapy and pharmacology, 80 (1), 1-14.
Baker, N. M., Rajan, R., Mondragon, A. (2009). Structural studies of type I topoisomerases. Nucleic acids research, 37(3), 693-701.
Pendleton, M., Lindsey Jr, R. H., Felix, C. A., Grimwade, D., Osheroff, N. (2014). Topoisomerase II and leukemia. Annals of the New York Academy of Sciences, 1310(1), 98-110.
Bansal, S., Bajaj, P., Pandey, S., Tandon, V. (2017). Topoisomerases: Resistance versus sensitivity, how far we can go?. Medicinal research reviews, 37(2), 404-438.
Holden, J. A. (2001). DNA Topoisomerases as anticancer drug targets from the laboratory to the clinic. Current Medicinal Chemistry-Anti-Cancer Agents, 1(1), 1-25.
Hande, K. R. (2008). Topoisomerase II inhibitors. Update on cancer therapeutics, 3(1), 13-26.
DeVita, V. T., Lawrence, T. S., Rosenberg, S. A. (2019). Cancer: p